liraglutide glp 1 agonist vs Semaglutide vs GLP-1 GLP-1 Agonists for Weight Loss:

Abstract Aims/hypothesis We aimed to determine whether the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) in individuals with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus decreases the risk of new-onset adverse cardiovascular events (CVEs) and mortality rate compared with other glucose-lowering drugs in a real setting at a population level

However, humans and mice display large differences

Front Endocrinol (Lausanne) 2022;13:1033479

[DOI] [PMC free article] [PubMed] [Google Scholar] 157.Feuer DS, et al

These effects promote weight loss and improve glycemic control

Set realistic expectations Emphasizing the importance of understanding the journey of weight loss and maintenance, and redirecting focus towards overall health and well-being, can empower patients to approach their weight management goals holistically